Alzheimer’s Diagnosis – False Diagnosis, False Claims of Effective Drugs

Majid Ali, M.D.

False Diagnosis:

53.3% of Patients With Amyloid Plaque; 0.5% of Patients With Mild Cognitive Impairment

False Claims of  Alzheimer’s Drugs:

All four Approved Drugs Do Not Works ((Nature. 13 July 2017)


 

In 1994, in my book RDA: Rats, Drugs, and Assumptions, I put forth my Oxidative Model of Alzheimer’s disease (AD) and explained how the disease begins and progresses as a result of cumulative oxidative injury caused by toxic foods and environmental toxins. In 2004, I presented evidence for mitochondrial dysfunction and respiratory-to-fermentative shift in chronic diseases in a paper published in the journal Townsend Letter. That led me to revise and expand the oxidative model of AD to Oxygen Model of AD. I explained why diagnosis of Alzheimer’s disease (AD) continues to be questionable in many cases. Below is the link to a report in The Washington Post. I follow it with comments about why the use of the prevailing diagnostic criteria for AD is problematic. I add here that after decades of false claims, no “Alzheimer’s drugs have been proven effective according to the journal Nature , as reported 13 July 2017 (Nature. 2017;547: pages 153-155.) 

http://www.sciencemag.org/news/sifter/some-alzheimer-s-patients-might-have-been-misdiagnosed-study-suggests


 

Alzheimer’s disease can be hard to definitively diagnose, but one study’s findings could make the process much easier and more accurate. Interim results from a 4-year analysis suggest that a substantial number of patients being treated for the condition may not have it at all, The Washington Post reports. The presence of amyloid plaque in the brain precedes Alzheimer’s and can be detected by costly positron emission tomography (PET) scans, which are not usually covered by insurance. Therefore, doctors often diagnose and treat patients for the disorder based on symptoms. After administering PET scans to 4000 people previously diagnosed with either mild cognitive impairment (MCI) or dementia and treated for Alzheimer’s to test for the presence of amyloid plaque, only 53.3% of patients with MCI and 70.5% with dementia tested positive. Following the results, doctors changed the care plans of two-thirds of the patients involved in the study, presenters said at the Alzheimer’s Association International Conference in London. Researchers hope the results will move the Centers for Medicare & Medicaid Services to cover PET scans through Medicare.


 

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s